BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MedNet - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MedNet
X-ORIGINAL-URL:https://mednetus.net
X-WR-CALDESC:Events for MedNet
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230301T080000
DTEND;TZID=America/New_York:20240301T170000
DTSTAMP:20260424T091021
CREATED:20250620T075226Z
LAST-MODIFIED:20250620T075226Z
UID:10000019-1677657600-1709312400@mednetus.net
SUMMARY:Glaucoma: Sustained-release Drug Delivery System\, Topical Agents\, and Emerging 3D Visualization Technologies
DESCRIPTION:CME | CNE 1.00 Credit \n\n\n\nWebcast \nTime to Complete: 1 hour \nReleased: March 1\, 2023 \nExpires: March 1\, 2024 \nMaximum Credits:\n1.00 / AMA PRA Category 1 CreditTM\n1.00 / ANCC Contact Hour \nProgram Description \nGlaucoma is a heterogeneous group of diseases that has become a significant cause of irreversible blindness worldwide. A glaucoma group of optic neuropathies is characterized by progressive degeneration of retinal ganglion cells. These are central nervous system neurons with cell bodies in the inner retina and axons in the optic nerve. Degeneration of these nerves results in cupping\, a characteristic optic disc appearance\, and visual loss. The biological basis of glaucoma is poorly understood\, and the factors contributing to its progression have not been fully characterized. \nIntended Audience \nThis webcast is designed to meet the educational needs of ophthalmologists\, optometrists\, retina specialists\, advanced practice providers\, and nurses caring for a patient with glaucoma. \nCommercial Supporter \nThis activity is supported by an educational grant from Alcon Vision\, LLC. \n\nEducational Objectives \nUpon completion of the educational activity\, participants should be able to: \n\nSummarize the pathophysiology of glaucoma development\nAssess clinical trial data on new sustained-release drug delivery systems and topical agents in the management of glaucoma\nAppraise the utility of 3D visualization in glaucoma surgery\n\nAccredited Providers \nThis activity is provided by Amedco\, a CME/CE company\, and MedNet. \n  \nJoint Accreditation Statement \n \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. \nPhysicians (ACCME) Credit Designation \nDesignation Statement \nAmedco LLC designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nNurses (ANCC) Credit Designation \nDesignation Statement \nAmedco LLC designates this activity for a maximum of 1.00 ANCC contact hour. \nAdditional Credit Information \nNote to Physician Assistants\nPAs may claim a maximum of 1.00 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME or a recognized state medical society \nNote to Nurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allows reciprocity for AANPCP continuing education credit for a maximum of 1.00 hour. \nConflicts of Interest Policy \nIt is the policy of the Amedco to ensure activity content is balanced\, independent\, objective and based on scientific best-evidence. All persons in a position to control content (i.e.\, course director\, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation. \nEvery person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose. \nPlanners’ and Managers’ Disclosures \nThe planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast: \nKamatham A. Naidu\, PhD (MedNet) has no relevant financial relationships.\nBrian Waggoner (MedNet) has no relevant financial relationships to disclose.\nSheryl Morgan (Amedco) has no relevant financial relationships to disclose. \nDisclosure of Unlabeled Use \nIt is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label\, unlabeled\, experimental\, and/or investigational (not FDA approved) and of any limitations on the information that is presented\, such as data that are preliminary or that represent ongoing research\, interim analyses\, and/or unsupported opinion. \nEach speaker reported he/she will notify the audience if/when discussion includes off-label\, unlabeled\, experimental\, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation. \nDisclaimer \nThe information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. \nNon-Endorsement of Products \nAmedco do not imply either real or implied endorsement of any product\, service\, or company referred to in this educational activity. \nFaculty \nRobert Chang\, MD\nAssociate Professor of Ophthalmology\nStanford University\nPalo Alto\, CA \nDr. Chang discloses the following:\nResearch support: Alcon and Genentech\nConsultant: Alcon\, Genentech\, 1800 Contacts\, Verana Heath\, Sight Sciences\, Ocular Therapeutix\, Apple\, and Belken\nAdvisor: Smartlens and XP Health\nSPV: Iantrek \nFelipe A Medeiros\, MD\, PhD\nJoseph AC Wadsworth Distinguished Professor of Ophthalmology\nProfessor of Electrical and Computer Engineering\, and Biostatistics\nDuke University\, Durham\, NC \nDr. Medeiros discloses the following:\nResearch support: National Eye Institute R01 EY029885\, R43 EY027651\, Carl-Zeiss Meditec\, Inc.\, Heidelberg Engineering\, GmBH\, Reichert\, and Google\, Inc.\nConsultant: Allergan\, Inc.\, Novartis\, Inc.\, Reichert; \, Carl-Zeiss\, Inc.\, Galimedix\, Biogen\, Stealth Therapeutics\, Annexon \nInstructions \nThere are no fees for participating and receiving CME/CE credit for this webcast. During the period from March 1\, 2023\, through March 1\, 2024\, participants must read all the material and study the educational webcast. \nThis webcast includes text\, graphics\, and may include multimedia features. \nIn order to receive CME/CE credits\, participants must complete the pre-assessment questions\, post-assessment\, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript\, which you can access at any time. \nIf you have any questions relating to the accreditation of this activity\, please contact the CME/CE Provider at certificate@amedcoemail.com. \nPrivacy Policy \nAmedco observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities that are relevant to their interests and/or the activities they support. \nmyCME privacy policy
URL:https://mednetus.net/event/glaucoma-sustained-release-drug-delivery-system-topical-agents-and-emerging-3d-visualization-technologies/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/s3oowug5n25y-800x450-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221130
DTEND;VALUE=DATE:20221201
DTSTAMP:20260424T091021
CREATED:20250620T075835Z
LAST-MODIFIED:20250620T075835Z
UID:10000020-1669766400-1669852799@mednetus.net
SUMMARY:New Paradigms in the Clinical Practice of Inflammatory Bowel Diseases - Live Event
DESCRIPTION:November 30\, 2022 \n\n\nTake Me to the Event Registration\n\n\nEVENT Summary \nDates \nWednesday\, November 30\, 2022\, 7:00 PM EDT \nLocation \nVirtual \nTarget Audience \nGastroenterologists\, internal medicine specialists\, primary care physicians\, nurse practitioners\, physician assistants\, and nurses caring for patients with inflammatory bowel diseases (IBDs) \nFormat \nLive Webinar \nCredits \n1.25 / AMA PRA Category 1 Credit(s)TM\n1.25 / ANCC Contact Hours \nCost \nFree \nProgram Description \nClick to Go to the Event Registration \nInflammatory bowel diseases (IBD)\, commonly categorized as Crohn’s disease (CD) and ulcerative colitis (UC)\, are immune mediated chronic inflammatory disorders of the gastrointestinal tract. The etiopathogenesis is multifactorial\, with different environmental\, genetic\, immune mediated\, and gut microbial factors playing an important role. The current therapy goals are to improve clinical symptoms\, control inflammation\, prevent complications\, and improve quality of life. Different therapeutic agents are available with their indications\, mechanisms of action\, and side effects. The field of IBD therapeutics has seen tremendous improvements\, and the efficacy of new drug targets such as IL-12/IL-23\, the JAK/STAT pathway\, and S1P has been established. \nAgenda \n\nRole of the drug targets such as S1P\, the JAK/STAT\, the IL-12/IL-23 pathway\, and biosimilars in managing IBD – Miguel Regueiro\, MD\nCase Presentation 1 – Miguel Regueiro\, MD\nDiscuss the interdisciplinary management of extra-intestinal manifestations in people living with IBD – Francis Farraye\, MD\nCase Presentation 2 – Farraye\, MD\nQ&A from the Audience and Panel Discussion – Miguel Regueiro\, MD/Francis Farraye\, MD\n\nIntended Audience \nGastroenterologists\, internal medicine specialists\, primary care physicians\, nurse practitioners\, physician assistants\, and nurses caring for patients with inflammatory bowel diseases (IBDs). \nCommercial Supporters \nSupported by educational grants from Pfizer Inc. and Bristol Myers Squibb. \nLearning Objectives \n\nIncorporate biologics\, small molecule inhibitors\, and biosimilars in the treatment of inflammatory bowel diseases (IBD)\nAssess the interdisciplinary management strategies of extra-intestinal manifestations in people living with IBD\n\nAccredited Providers \nJointly provided by Amedco\, a CME/CE company\, and MedNet \n       \nJoint Accreditation \n \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MEDNET. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. \nPhysicians (ACCME) Credit \nDesignation Statement \nAmedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nNurses (ANCC) Credit \nDesignation Statement \nAmedco LLC designates this activity for a maximum of 1.25 ANCC contact hours. \nAdditional Credit Information \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Maximum of 1.25 hours. \nPhysician Assistants\nAAPA accepts AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME. Maximum of 1.25 hours. \nStaff Disclosures \nThe planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: \n\nKamatham A. Naidu\, PhD (MedNet) has no relevant financial relationships.\nBrian Waggoner (MedNet) has no relevant financial relationships to disclose.\nSheryl Morgan (Amedco) has no relevant financial relationships to disclose.\n\nFaculty \n \nMiguel Regueiro\, MD\nProfessor\, Department of Medicine\nChair\, Digestive Disease and Surgery Institute\nChair\, Department of Gastroenterology\, Hepatology\, and Nutrition\nThe Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology\nCleveland Clinic Lerner College of Medicine of Case Western Reserve University\nCleveland\, OH \n \nFrancis Farraye\, MD\nProfessor of Medicine\nDirector\, Inflammatory Bowel Disease Center\nDivision of Gastroenterology and Hepatology\nMayo Clinic\nJacksonville\, Florida \nInstructions/Technical Requirements \n\nA desktop or laptop computer with a stable internet connection and audio capability is required to attend. Joining via mobile or tablet is possible but not recommended.\nTimes in the portal adjust to your computer; however\, some browsers have a separate time zone adjustment.\nFor the best viewing experience\, we recommend the following browsers: Chrome\, Firefox\, and Safari. For attendees viewing on Internet Explorer 11\, you may experience lags in streaming. To maximize your attendee hub experience\, we recommend you not sign in through your company assigned VPN.\nEnsure that your computer’s sound is enabled for your browser and allow permissions to the On24 Attendee Hub platform if necessary.\n\nCost \nComplimentary \nContact \nBrian Waggoner\nProgram Manager\nMedNet\nbrianw@mmhus.net
URL:https://mednetus.net/event/new-paradigms-in-the-clinical-practice-of-inflammatory-bowel-diseases-live-event/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/az67bbjmkb29-Oveview800x450.jpg
END:VEVENT
END:VCALENDAR